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ABSTRACT
Cancer including melanoma may be ‘‘addicted” to double strand break (DSB) 
repair and targeting this process could sensitize them to the lethal effect of DNA 
damage. PARP1 exerts an important impact on DSB repair as it binds to both single- 
and double- strand breaks. PARP1 inhibitors might be highly effective drugs triggering 
synthetic lethality in patients whose tumors have germline or somatic defects in 
DNA repair genes. We hypothesized that PARP1-dependent synthetic lethality could 
be induced in melanoma cells displaying downregulation of DSB repair genes. We 
observed that PARP1 inhibitor olaparib sensitized melanomas with reduced expression 
of DNA ligase 4 (LIG4) to an alkylatimg agent dacarbazine (DTIC) treatment in vitro, 
while normal melanocytes remained intact. PARP1 inhibition caused accumulation 
of DSBs, which was associated with apoptosis in LIG4 deficient melanoma cells. Our 
hypothesis that olaparib is synthetic lethal with LIG4 deficiency in melanoma cells 
was supported by selective anti-tumor effects of olaparib used either alone or in 
combination with dacarbazine (DTIC) in LIG4 deficient, but not LIG4 proficient cells. 
In addition, olaparib combined with DTIC inhibited the growth of LIG4 deficient human 
melanoma xenografts. This work for the first time demonstrates the effectiveness of 
a combination of PARP1 inhibitor olaparib and alkylating agent DTIC for treating LIG4 
deficient melanomas. In addition, analysis of the TCGA and transcriptome microarray 
databases revealed numerous individual melanoma samples potentially displaying 
specific defects in DSB repair pathways, which may predispose them to synthetic 
lethality triggered by PARP1 inhibitor combined with a cytotoxic drug.
INTRODUCTION
While melanomas can be successfully treated in 
the early stages, the appearance of metastasis in distant 
organs worsens prognosis and drops median survival 
below nine months [1]. Despite of the recent advances 
in melanoma treatment, including immunotherapies 
and targeted therapies, a resistance is developed in 
the majority of patients [2] indicating that genotoxic 
therapies might still be needed. It has been suggested 
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that cancer cells survive genotoxic stress due to 
acquired abnormalities in DNA repair system [3]. 
The 'addiction' of cancer cells to compensatory DNA 
repair mechanisms, especially double strand break 
(DSB) repair, may create an opportunity to target these 
pathways to eliminate malignant cells [3, 4].
DSBs are highly cytotoxic DNA lesions caused 
by reactive oxygen species (ROS), ionizing radiation 
and genotoxic drugs [4]. In proliferating cells DSBs are 
usually repaired by two major mechanisms, BRCA1/
BRCA2-dependent homologous recombination (HR) 
and DNA-PKcs-mediated non-homologous end-joining 
(D-NHEJ), whereas PARP1-dependent back-up NHEJ 
(B-NHEJ) serves as an alternate mechanism [5–7]. In 
addition, PARP1 may decrease the number of potentially 
lethal DSBs, either by stimulation of base excision repair 
(BER) and single-strand break (SSB) repair and/or by 
facilitation of MRE11-mediated recruitment of RAD51, 
as well as, by involvement in relocation of XRCC1, an 
essential protein for an effective DSB repair and restart of 
stalled replication forks [8, 9].
It was reported that cells deficient in BRCA1/
BRCA2-mediated HR are sensitive to PARP1 inhibitors, 
such as the recently FDA approved olaparib (Lynparza, 
Astra-Zeneca) due to induction of synthetic lethality [10]. 
Since TCGA database analysis revealed that melanoma 
samples display deregulated expression and/or mutations 
of the genes encoding DSB repair proteins (Figure 1), we 
hypothesize that DSB repair deficiencies could sensitize 
individual melanomas to PARP1 inhibitor administered 
either alone or in combination with DSB-inducing 
genotoxic agents, such as dacarbazine (DTIC) [11].
RESULTS
Genes involved in the DSB repair pathway 
are differentially expressed in patient-derived 
melanoma cells and in normal melanocytes
To test the potential anti-melanoma effect of PARP1 
inhibitors we established six patient-derived melanoma 
cell lines. Real-time PCR was used to determine the 
gene expression profile in melanoma cells and in normal 
human melanocytes. Eight genes were examined, whose 
products are essential for DSB repair pathways (BRCA1, 
PALB2, and RAD51 in HR; PRKDC, XRCC6, and LIG4 
in D-NHEJ; PARP1 and LIG3 in B-NHEJ). Significant 
differences were found in the gene expression profiles 
between melanoma cells and melanocytes. In particular, 
all melanoma lines showed a decreased level of DNA 
ligase 4 (LIG4) (Figure 2A).
Protein expression status of LIG4, RAD51, PARP1, 
Ku70 was determined by Western blot analysis in 
normal melanocytes and melanoma cell lines (DMBC11, 
DMBC12) (Figure 2B). Both DMBC11 and DMBC12 cell 
lines displayed elevated expression of RAD51, PARP1 
and Ku70 proteins, whereas expression of LIG4 was 
downregulated.
Olaparib used either alone or in combination 
with DTIC induced cytotoxic effects in patient-
derived LIG4-deficient melanoma cells
To determine the influence of tested compounds 
on viable cell number, plasma membrane integrity was 
measured by cytometric analysis (Figure 3A). After 
Figure 1: Analysis of TCGA database of 287 individual skin cutaneous melanomas. Deregulated expression (Z-score >2.0) 
and/or mutations of the genes in DSB repair pathways, HR and D-NHEJ, are shown.
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the first 48 hours of treatment, only the combination of 
olaparib and DTIC markedly reduced viability reaching 
about 54% of control. The second dose and additional 
incubation for 72 hours induced cell response to drugs, 
used either alone or in combination. Normal melanocytes 
were not affected by the treatments.
Cell death was assessed by the appearance of sub-
diploid fraction (subG1, Figure 3B). Sub-diploid DNA 
content was found in about 55% in DMBC11 cells and 34% 
in DMBC12 cells after combined treatment with olaparib 
and DTIC for 48 hours, and this effect was further increased 
with the next dose and prolonged treatment. This might 
indicate that these compounds were more likely to induce 
cell death than cytostatic effects in melanoma cells, which 
was further confirmed by cell cycle analysis. Cell cycle 
arrest was not clearly visible in olaparib or DTIC treated 
melanoma cells, and only a modest fraction of cells treated 
with olaparib + DTIC accumulated in G2/M (Figure 3C).
Figure 2: Expression profiles of DNA double-strand break repair genes in melanoma cells compared to melanocytes. 
A. The transcript level of each gene was normalized to the expression of a reference gene (18S RNA). Data is presented as fold change in 
melanoma cells versus melanocytes, in which expression levels of the genes were set as 1. The mean values ± SD were calculated from 
3 experiments performed in triplicates. B. The protein level was normalized to the expression of a reference protein, GAPDH. Data is 
presented as fold change in melanoma cells versus melanocytes, in which the expression levels of the proteins were set as 1. The means ± 
SD were calculated from 3 experiments. Representative Western blot results are included.
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Figure 3: Effects of olaparib and DTIC, used alone or in combination, on viability, distribution in cell cycle and 
clonogenicity of melanoma cells. A. Viability was measured using PI staining and flow cytometry, and it is shown as % of vehicle 
control. Means ± SD of 2 independent experiments performed in triplicates are shown. B. Cell death was measured by accumulation of 
melanoma cells in the sub-G1 fraction; mean ± SD of 2 independent experiments. C. Distribution of melanoma cells through the cell-cycle 
phases was analyzed by flow cytometry. Left panel, bars represent cell distribution after 48 hours and after additional 72 hour treatments 
of DMBC11 and DMBC12 populations with DTIC and olaparib, used alone or in combination. ModFit LT 3.0 software was used to 
calculate the percentages of cells in each fraction; means ± SD of two independent experiments are shown. Right panel, representative 
histograms of DMBC11 cells treated with two doses of indicated drugs (48 hours followed by 72 hours). D. Clonogenic assay showing the 
long-term effects olaparib and/or DTIC on melanoma cell lines DMBC11 and DMBC12. Left panel, bars represent clonogenic efficiency 
in drug-treated melanoma cell populations, expressed as percentages of clonogenic efficiency in vehicle-treated control; mean ± SD of 2 
independent experiments. Right panel, photographs of a representative experiment are shown.
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Soft agar was used as a semisolid support to obtain 
spatially distinct colonies. When used alone, DTIC and 
olaparib reduced the number of colonies (Figure 3D). 
When drugs were used in combination, the clonogenic 
efficiency was further reduced.
To validate the importance of reduced level of LIG4 
on the susceptibility of melanoma cells to olaparib, LIG4 
was ectopically expressed in DMBC11 cell line (Figure 
4A). Elevated expression of LIG4 reduced the sensitivity 
of DMB11 cells to olaparib (Figure 4B). Moreover, LIG4-/- 
pre-B cells were more sensitive to olaparib treatment than 
parental cells expressing endogenous LIG4 (Figure 4C).
Olaparib and DTIC, used alone or in 
combination, increase the number of DSBs in 
patient-derived LIG4 deficient melanoma cells
In normal melanocytes the level of phosphorylated 
γ-H2AX, which marks DSBs [12], remained unchanged 
after the treatment. However, DMBC11 and DMBC12 cell 
lines showed increased levels (5- or 2-fold, respectively) 
of phosphorylated γ-H2AX in comparison to melanocytes 
(Figure 5A). Moreover, combined treatment approximately 
doubled the level of phosphorylated γ-H2AX in both 
melanoma cell lines in comparison to cells treated with 
either drug alone.
The neutral comet assay was also used to measure 
the ability of olaparib and/or DTIC to induce DSBs 
as described before [13]. DMBC11 and DMBC12 cell 
lines treated with individual drugs showed increased 
intensity of DNA tail in comparison to melanocytes 
indicating accumulation of DSBs (Figure 5B). Moreover, 
combination of olaparib and DTIC caused more DSBs that 
individual drug.
Olaparib and DTIC combination reduces 
melanoma growth in NSG mice
Sub-optimal doses of olaparib or DTIC did not 
reduce the growth of DMBC11 cells in NSG mice (Figure 
6). Interestingly, the combination of olaparib and DTIC 
exerted modest, but statistically significant anti-melanoma 
effect. Stronger effect would probably require optimization 
of the treatment protocol.
DISCUSSION
Synthetic lethality is a phenomenon occurring when 
simultaneous depletion of a pair of genes or gene products 
is required for cell death to occur. For example, cells 
harboring BRCA1/2 inactivating mutations are sensitive 
to PARP1 inhibitors [14, 15]. Therefore, PARP1 inhibitors 
may be highly effective drugs in variety of tumors with 
germline or somatic defects in DNA damage repair genes. 
In the present study we showed that PARP1 inhibitor 
olaparib applied alone and in combination with DTIC (a 
drug used in melanoma treatment) was effective against 
melanoma cells displaying downregulation of LIG4 
without affecting normal melanocytes. This effect was 
associated with accumulation of toxic DSBs, implicating 
olaparib-mediated synthetic lethal effect in LIG4 deficient 
melanoma cells. Downregulated LIG4 and/or Artemis were 
Figure 4: Sensitivity to olaparib depended on LIG4 expression levels. A. Quantification of normalized LIG4 levels to GAPDH 
in total cell lysates obtained from GFP+ DBM11 cells transfected with expression plasmids encoding GFP or GFP and LIG4. Bars represent 
mean percentage volume intensity ± SD from 3 experiments; *p < 0.001 in comparison with GFP. Representative Western blots of the 
expression of LIG4 and GAPDH (loading control) are shown. B. The effect of olaparib on viability of DMBC11 cells transfected with 
GFP or GFP + LIG4. Results represent mean ± SD from 3 independent experiments; **p < 0.05 in comparison with GFP. C. The effect 
of olaparib on viability of Nalm6 parental and Nalm6 LIG4-/- pre-B cells. Results represent mean ± SD from 3 independent experiments.
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detected before in cell lines established from high-risk 
neuroblastomas and therapy-resistant breast carcinomas 
[16, 17]. However, these studies did not establish that 
sensitivity to PARP1 inhibitors depended on inhibition 
of LIG4. Our work for the first time demonstrates that 
downregulation of LIG4 in melanoma cells is directly 
responsible for enhanced sensitivity to olaparib.
Our results suggest the new therapeutic approach 
against melanomas based on synthetic lethality which 
exploits the reduced levels of LIG4, an essential 
component of D-NHEJ that performs the final ‘end 
processing' step of DSB repair [18]. When LIG4 
expression is reduced, D-NHEJ repair is performed 
inefficiently, and additional inhibition of PARP1-dependent 
B-NHEJ, BER and/or replication fork restart by olaparib 
could result in accumulation of toxic DSBs [5, 7–9]. 
Altogether, we postulate that D-NHEJ deficiency caused 
by downregulation of LIG4 could be synthetically lethal 
with B-NHEJ deficiency induced by PARP1 inhibitor. 
This hypothesis is supported by the results showing that 
PARP inhibitors were selectively toxic to LIG4-deficient 
melanoma and leukemia cells (this work) and that they 
Figure 5: Olaparib and/or DTIC induced DSBs in melanoma cell lines (DMBC11, DMBC12). Cells were treated with 5 μM 
olaparib and/or 2 mM DTIC for 48 hrs (comet assay) and 120 hrs (γ-H2AX). A. The mean values ± SD of γ-H2AX were calculated from 
3 ELISA experiments performed in triplicates. B. The mean percentage ± SD of DNA in the tails of comets in neutral conditions acquired 
from one hundred cells/group from 3 experiments. *p<0.05 and **p<0.001 in comparison with control.
Figure 6: Combination of olaparib and DTIC reduced the growth of human melanoma in immunodeficient mice. NAG 
mice were injected s.c. with DMBC11 melanoma cells followed by the treatment with olaparib (35 mg/kg twice a day), DTIC (8 mg/kg 
every second day), or olaparib + DTIC. Data represent mean ± SD of tumor mass from 2 independent experiments, *p<0.05 in comparison 
with untreated mice.
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increased DNA damage induced by radiation exposure in 
LIG4-/- HCT116 colon carcinoma cell line [19].
Although downregulation/mutation of LIG4 (and its 
partner XRCC4) was detected only in approximately 7% 
of cutaneous melanomas in TCGA database (Figure 1), 
inhibition/inactivating mutation of other members of 
D-NHEJ potentially impairing DSB repair activity by the 
pathway were detected, too [20]. Moreover, transcriptome 
analysis by microarrays of 229 melanoma cell lines 
detected downregulation of at least one member of 
D-NHEJ pathway (including LIG4) in numerous samples 
established from patients manifesting different stages of 
malignancy (Figure 7A). The 229 melanoma cells were 
grouped by their molecular phenotype, proliferative, 
intermediate and invasive. The proliferative phenotype is 
defined by high expression of MITF and low expression 
of WNT5A, the invasive phenotype is defined by low 
expression of MITF and high expression of WNT5A, 
and intermediate phenotype have approximately equal 
expression of MITF and WNT5A. From the analysis, 
it seems that the invasive phenotype has greater 
downregulation in the D-NHEJ genes than proliferative, 
Figure 7: Transcriptome microarrays analysis of expression of the genes in A. D-NHEJ pathway, and B. HR pathway 
from 229 melanoma cell lines established from patients manifesting the following phenotypes: A- proliferative, C- 
invasive, and B- intermediate. Percent above column color bar represents number of samples with at least one downregulated gene 
within the phenotype group.
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therefore selected melanomas with an invasive phenotype 
should display enhanced sensitivity to PARP1 inhibitors.
In addition, multiple melanoma samples displayed 
downregulation of at least one gene in HR pathway (Figure 
7B) with higher frequency in the invasive phenotype 
suggesting their sensitivity to synthetic lethality triggered by 
PARP1 inhibitors [21]. In concordance, inhibition of histone 
deacetylases class I resulted in suppression of HR due to 
down-regulation of RAD51 and FANCD2 and sensitized 
malignant melanoma cells to a synthetic lethal effect of 
olaparib combined with alkylating drug temozolomide [22].
Despite downregulation/mutations of DSB 
repair genes detected in numerous samples in TCGA 
and transcriptome microarray databases, melanomas 
typically do not respond well to DNA damaging agents. 
Perhaps the degree of downregulation of DNA repair 
genes is not strong enough to increase the sensitivity 
to chemotherapeutics in clinical settings. However, as 
suggested by this work, the effect may become clinically 
relevant in repair-deficient cells when a genotoxic drug is 
combined with PARP1 inhibitor, which further enhances 
DNA damage beyond a reparable threshold.
In summary, PARP1 inhibitor seems to offer 
additional treatment opportunity to pre-selected melanomas 
displaying LIG4 (and/or XRCC4) deficiency. In addition, 
analyses of the already existing databases strongly 
suggest that numerous melanomas could be sensitive to 
personalized medicine-guided PARP1 inhibitor-mediated 
synthetic lethality due to their putative deficiencies in 
DNA repair pathways. This speculation is supported by 
phase II study showing almost doubled (although not 
statistically significant) progression-free survival of the 
patients with metastatic melanoma treated with veliparib 
+ temozolomide compared with placebo + temozolomide. 
Perhaps personalized medicine approach is necessary 
to pre-select patients with melanomas predisposed to 
synthetic lethality mediated by PARP1 inhibitor.
MATERIALS AND METHODS
In vitro cell cultures
Melanoma cell lines derived from surgical 
specimens of nodular (DMBC2, DMBC8, DMBC9, 
DMBC10, DMBC12) and superficial spreading melanoma 
(DMBC11) were established in the Department of 
Molecular Biology of Cancer. The study was approved 
by the Ethical Commission of the Medical University 
of Lodz, and informed consent was obtained from all 
patients. Melanoma cells were cultured in Stem Cell 
Medium (SCM) as described elsewhere [23, 24]. Normal 
Human Melanocytes (NHEMs – Ad, Lonza) were cultured 
in Melanocyte Cell Basal Medium (MBM) (CC-3250, 
Lonza) supplemented with growth supplements according 
to the manufacturer’s protocol. Nalm6 parental and Nalm6 
LIG4-/- pre-B cells were purchased from HORIZON 
(www.horizondiscovery.com) and cultured in RPMI 
medium with 10% FBS (Lonza) and antibiotics (100 IU/
ml penicillin, 100 mg/ml streptomycin (Gibco) at 37°C in 
a humidified atmosphere containing 5% CO2.
Drug treatment
Melanoma cells and NHEMs were plated at a 
density of 1 x 105 viable cells per well in a 6-well plates 
one day before drug treatment. Cells were cultured with 
5 μM olaparib (Selleckchem), 2 mM dacarbazine (DTIC) 
(Sigma Aldrich), olaparib + DTIC, or vehicle. After 
48 hours, half the cell suspension from each well was 
taken to determine cell viability after propidium iodide 
(PI) staining and cell cycle analysis. Following this, 
1 ml of fresh medium containing drugs at appropriate 
concentrations was added to the remaining cell culture for 
additional 72 hours of culturing.
Clonogenic assay
Melanoma cells were first incubated with 
compounds at indicated concentrations for 48 hours 
and then for 72 hours. Then, 1000 single viable cells 
were transferred to soft agar and clonogenic assay was 
performed as previously described [23].
Flow cytometry
Flow cytometry and propidium iodide (PI) 
staining was used to assess changes in viability and cell 
distribution in cell cycle phases. Cells were analyzed 
using a FACSVerse flow cytometer (Becton Dickinson, 
San Jose, California, USA). ModFit LT 3.3 software 
(Verity Software, Topsham, Minnesota, USA) was used to 
calculate the percentage of cells in each cell-cycle phase 
and FACSuit software (Becton Dickinson) was used to 
calculate the percentages of dead cells in subG1.
Ectopic expression of LIG4
Melanoma DMBC11 cells were transfected with 
plasmid pCMV6-AC-GFP with cloned human LIG4 
cDNA (OriGene Technologies) using lipofectamine 3000 
(Invitrogen) according to the manufacturer's protocol. 
GFP+ cells were sorted after 48 hrs and used for the 
experiments.
Transcriptome microarrays analysis
Microarray data was obtained from NCBI GEO and 
analyzed for phenotype classes proliferative, intermediate 
and invasive as described in Widmer et al [25]. Microarray 
was subset for D-NHEJ genes and HR genes. Z-score 
cutoffs were set at 1.5 and 2 to detect upregulated 
and downregulated genes. Samples with at least one 
downregulated gene were counted.
Oncotarget9www.impactjournals.com/oncotarget
RNA isolation, cDNA synthesis and Real-Time 
PCR
Isolation and purification of RNA was performed 
using total RNA isolation kit (A&A Biotechnology). 
Subsequently, RNA was transcribed into cDNA using 
SuperScript II Reverse Transcriptase (Invitrogen Life 
Technologies, Carlsbad, California, USA). qRT-PCR was 
performed using TaqMan® Real-Time PCR Master Mix 
(Life Technologies) and Agilent Technologies Stratagene 
Mx300SP working on MxPro software. TaqMan probes 
(Life Technologies) were used to analyze 8 genes whose 
products are essential for DSB repair pathways (BRCA1, 
LIG3, LIG4, PALB2, PARP1, PRKDC, RAD51, XRCC6), 
and 18S RNA (Life Technologies) was included as the 
reference gene. The cycling parameters were 95°C for 10 
minutes, 30 cycles of 95°C for 15 seconds and 60°C for 
60 seconds.
Western blot analysis
Cell lysates were obtained by incubating a cell 
pellet with RIPA buffer for 30 minutes. Lysates were 
than resolved by SDS-PAGE. The proteins were 
transferred onto an Immobilon-P PVDF membrane 
(Millipore), which were blotted overnight with primary 
antibodies recognizing GAPDH, DNA LIG4 (Santa Cruz 
Biotechnologies), Ku70, RAD51 or PARP1 (ThermoFisher 
Scientific). This was followed by 1 h incubation with 
secondary antibodies conjugated with HRP (Anti-Mouse 
and Anti-Rabbit antibodies, Cell Signaling).
ELISA measurement of γ-H2AX
Cell lines DMBC11, DMBC12 and NHEMs 
were cultured with vehicle or with drugs on black 96-
well plates with a clear bottom. Analysis of the level of 
phosphorylated histone γ-H2AX was performed using an 
H2AX Phosphorylation Assay Kit (Millipore, Billerica, 
MA, USA according to the protocol. Chemiluminescence 
detection was performed using attached HRP-substrates 
using a GloMax-Multi device (Promega). Bleomycin at 35 
μM for 30 min was used as a control.
Neutral comet assay measurement of DSBs
Cells were cultured with vehicle or drugs for 48 
hours and analyzed by neutral version of comet assay to 
detect DSBs as described before with modifications [13]. 
Briefly, cells were suspended in 0.75% LMP agarose 
and casted onto microscope slides precoated with 0.5% 
NMP agarose. The cells were then lysed for 1 h at 4 °C 
in a buffer consisting of 2.5 mM NaOH, 100 mM EDTA, 
1% Triton X-100, 10 mM Tris, pH 10. After the lysis the 
slides were placed in an electrophoresis unit, DNA was 
allowed to unwind for 20 min in the electrophoresis buffer 
consisting of 100 mM Tris and 300 mM sodium acetate at 
a pH adjusted to 9.0 by glacial acetic acid. Electrophoresis 
was conducted in this electrophoresis buffer at 4 °C for 60 
min at an electric field strength of 0.41 V/cm (100 mA). 
The slides were then washed in water, drained and stained 
with 2 μg/ml of DAPI and examined at 200× magnification 
in an Eclipse fluorescence microscope (Nikon, Tokyo, 
Japan) attached to COHU 4910 video camera (Cohu, 
San Diego, CA, USA) equipped with a UV-1 filter block 
consisting an excitation filter (359 nm) and a barrier filter 
(461 nm) and connected to a personal computer-based 
image analysis system, Lucia-Comet v. 5.41 (Laboratory 
Imaging, Praha, Czech Republic). Fifty images were 
randomly selected from each sample and the percentage 
of DNA in the tail of comets (% tail DNA) was measured. 
The mean value of the % tail DNA in a particular sample 
was taken as an index of DSBs in the sample.
Xenograft experiments
24 NSG mice were injected subcutaneously under 
the right scapula with 1x105 melanoma cells previously 
suspended in Matrigel. After 4 days tumor-bearing mice 
were randomly assigned into four groups; untreated, and 
treated intraperitoneally either with olaparib (35 mg/
kg bodyweight twice a day, diluted in DMSO), DTIC (8 
mg/kg bodyweight every second day, diluted in PBS) or 
olaparib with DTIC (same dosing as in monotherapy) 
for 24 days. After the end of experiment tumors were 
collected and weighted. The study was approved by the 
local Ethical Committee.
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